Pechanova O, Kashiba M, Inoue M
21, 2025, the FDA announced that the semaglutide shortage was over and that compounding pharmacies need to stop making and selling semaglutide injection products that are copies of FDA-approved products (Ozempic, Wegovy, and Rybelsus)
The emergence of new medications and combination therapies may further fragment the market, driving down prices and restricting the market share for GLP-1 receptor agonists
It typically affects the upper arms, thighs, cheeks, and buttocks
Mold is estimated to cover about 25% of the worlds biomass, with about 100,000 fungal species of mold identified (1)
When these issues compound, GLP-1s become a line item with no end in sight